View in EDS

A standing platform for cancer drug development using ctDNA-based evidence of recurrence.

Saved in:
Bibliographic Details
Title: A standing platform for cancer drug development using ctDNA-based evidence of recurrence.
Authors: Medford AJ; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Carmeli AB; Science for America, Cambridge, MA, USA., Ritchie A; Science for America, Cambridge, MA, USA., Wagle N; Genentech, South San Francisco, CA, USA., Garraway L; Genentech, South San Francisco, CA, USA., Lander ES; Broad Institute of MIT and Harvard, Cambridge, MA, USA. eric@broadinstitute.org.; Science for America, Cambridge, MA, USA. eric@broadinstitute.org.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA. eric@broadinstitute.org.; Department of Systems Biology, Harvard Medical School, Boston, MA, USA. eric@broadinstitute.org., Parikh A; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA. Aparna.Parikh@mgh.harvard.edu.
Source: Nature reviews. Cancer [Nat Rev Cancer] 2024 Nov; Vol. 24 (11), pp. 810-821. Date of Electronic Publication: 2024 Sep 30.
Publication Type: Journal Article; Review
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101124168 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-1768 (Electronic) Linking ISSN: 1474175X NLM ISO Abbreviation: Nat Rev Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39349822
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A standing platform for cancer drug development using ctDNA-based evidence of recurrence.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Medford+AJ%22">Medford AJ</searchLink>; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Carmeli+AB%22">Carmeli AB</searchLink>; Science for America, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Ritchie+A%22">Ritchie A</searchLink>; Science for America, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Wagle+N%22">Wagle N</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Garraway+L%22">Garraway L</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Lander+ES%22">Lander ES</searchLink>; Broad Institute of MIT and Harvard, Cambridge, MA, USA. eric@broadinstitute.org.; Science for America, Cambridge, MA, USA. eric@broadinstitute.org.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA. eric@broadinstitute.org.; Department of Systems Biology, Harvard Medical School, Boston, MA, USA. eric@broadinstitute.org.<br /><searchLink fieldCode="AU" term="%22Parikh+A%22">Parikh A</searchLink>; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA. Aparna.Parikh@mgh.harvard.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101124168%22">Nature reviews. Cancer</searchLink> [Nat Rev Cancer] 2024 Nov; Vol. 24 (11), pp. 810-821. <i>Date of Electronic Publication: </i>2024 Sep 30.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Review
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101124168 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-1768 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%221474175X%22">1474175X </searchLink><i>NLM ISO Abbreviation: </i>Nat Rev Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39349822
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41568-024-00742-2
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 810
    Titles:
      – TitleFull: A standing platform for cancer drug development using ctDNA-based evidence of recurrence.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Medford AJ
      – PersonEntity:
          Name:
            NameFull: Carmeli AB
      – PersonEntity:
          Name:
            NameFull: Ritchie A
      – PersonEntity:
          Name:
            NameFull: Wagle N
      – PersonEntity:
          Name:
            NameFull: Garraway L
      – PersonEntity:
          Name:
            NameFull: Lander ES
      – PersonEntity:
          Name:
            NameFull: Parikh A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2024 Nov
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1474-1768
          Numbering:
            – Type: volume
              Value: 24
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: Nature reviews. Cancer
              Type: main
ResultId 1